Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02889900
Title Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO)
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca
Indications

ovary serous adenocarcinoma

peritoneal carcinoma

fallopian tube carcinoma

ovarian clear cell carcinoma

endometrioid ovary carcinoma

Therapies

Cediranib + Olaparib

Age Groups: senior adult


No variant requirements are available.